Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 30, 2021 - Issue 7
Submit an article Journal homepage
639
Views
6
CrossRef citations to date
0
Altmetric
Review

Advances in the treatment of platinum resistant epithelial ovarian cancer: an update on standard and experimental therapies

Shuk on Annie Leunga Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA, USView further author information
&
Panagiotis A. Konstantinopoulosb Division of Gynecologic Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USCorrespondence[email protected]
View further author information
Pages 695-707 | Received 18 Mar 2021, Accepted 02 Jun 2021, Published online: 16 Jun 2021

Citations (6)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Rebecca L. Porter & Ursula A. Matulonis. (2023) Mirvetuximab soravtansine for platinum-resistant epithelial ovarian cancer. Expert Review of Anticancer Therapy 23:8, pages 783-796.
Read now
Seyed Aria Nejadghaderi, Maryam Balibegloo, Maryam Noori, Farimah Fayyaz, Amene Saghazadeh & Nima Rezaei. (2023) Clinical efficacy and safety of bispecific antibodies for the treatment of solid tumors: a systematic review and meta-analysis. Expert Review of Anticancer Therapy 23:3, pages 307-318.
Read now

Articles from other publishers (4)

Aizhi Geng, Hailei Yang, Zhenfeng Wang & Chuanzhong Wu. (2022) Apatinib plus paclitaxel versus paclitaxel monotherapy for platinum‐resistant recurrent ovarian cancer treatment: A retrospective cohort study. Journal of Clinical Pharmacy and Therapeutics 47:12, pages 2264-2273.
Crossref
Guochen Liu, Yanling Feng, Jing Li, Ting Deng, Aijun Yin, Lei Yan, Min Zheng, Ying Xiong, Jundong Li, Yongwen Huang, Chuyao Zhang, He Huang, Ting Wan, Qidan Huang, An Lin, Jie Jiang, Beihua Kong & Jihong Liu. (2022) A novel combination of niraparib and anlotinib in platinum-resistant ovarian cancer: Efficacy and safety results from the phase II, multi-center ANNIE study. eClinicalMedicine 54, pages 101767.
Crossref
Xiaodong Wu, Shizhen Shen, Jiale Qin, Weidong Fei, Fengyun Fan, Jiaxin Gu, Tao Shen, Tao Zhang & Xiaodong Cheng. (2022) High co‐expression of SLC7A11 and GPX4 as a predictor of platinum resistance and poor prognosis in patients with epithelial ovarian cancer . BJOG: An International Journal of Obstetrics & Gynaecology 129:S2, pages 40-49.
Crossref
Panagiotis A. Konstantinopoulos, Jung-min Lee, Bo Gao, Rowan Miller, Jung-Yun Lee, Nicoletta Colombo, Ignace Vergote, Kelly M. Credille, Suzanne R. Young, Samuel McNeely, Xuejing Aimee Wang, Aimee Bence Lin & Ronnie Shapira-Frommer. (2022) A Phase 2 study of prexasertib (LY2606368) in platinum resistant or refractory recurrent ovarian cancer. Gynecologic Oncology 167:2, pages 213-225.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.